Ubiquitech Software Corp. (UBQU) Explores Strategic Merger Opportunities in the Growing Specialty Materials and Advanced Textile Manufacturing Industry

Management Identifies Potential Opportunities Within Global Synthetic Fiber Market, Projected to Reach $144 Billion by 2033Tampa, Florida--(Newsfile Corp. - October...

Arthritis Foundation and Founding Sponsor Zimmer Biomet Announce New Community Celebrating Life After Joint Replacement and Inspiring Others to Act on Severe Joint Pain

The Comeback Club connects people who have had joint replacement with those considering it.ATLANTA and WARSAW, Ind., Oct. 26, 2026...

MEDSIR presents final TUXEDO-3 results highlighting the potential of patritumab deruxtecan in active brain metastases and leptomeningeal disease

The TUXEDO-3 study evaluates the efficacy of patritumab deruxtecan (HER3-DXd) for treating active brain metastases in patients with metastatic breast...

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience,...

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress

Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± chemotherapyCombinations demonstrated robust anti-tumor...

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate...

NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy...

error: Content is protected !!